Ticagrelor-Induced False-Negative Serotonin Release Assay in Heparin-Induced Thrombocytopenia With Stent Thrombosis Authors: Yasser Jamil, Rupinder K. Bahniwal, Andrew H. Nguyen, Edward Howard, Farhan Azad, William B. Ershler, Jamie L.W. Kennedy Published: 2026 ABSTRACT BackgroundHeparin-induced thrombocytopenia with thrombosis (HITT) is a prothrombotic complication of heparin, and diagnosis requires confirmatory testing with serotonin release assay (SRA).Case SummaryA 72-year-old man with ST-segment elevation myocardial infarction managed with drug-eluting stents and ticagrelor developed moderate-to-severe thrombocytopenia with multiterritory thrombosis (stent and extremity thrombosis). Two SRAs performed at separate intervals were negative. Ticagrelor was replaced with prasugrel, after which the SRA results became positive, confirming the suspicion of ticagrelor-induced false-negative SRA. Despite early initiation of bivalirudin and supportive measures, he developed multiorgan failure.DiscussionThis case highlights a diagnostic pitfall of the SRA in patients treated with ticagrelor, underscoring the need for heightened clinical awareness and alternative diagnostic strategies.Take-Home MessageClinicians should consider antiplatelet-related assay interference when evaluating suspected HITT to avoid delayed diagnosis and improve outcomes. Visual SummaryTimeline of the Patient's Clinical Course From Diagnosis of HITTADAMTS13 = a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; APLS = antiphospholipid syndrome; DES = drug-eluting stent; DVT = deep vein thrombosis; HIPA = heparin-induced platelet activation; HITT = heparin-induced thrombocytopenia with thrombosis; Ig = Immunoglobulin; PCI = percutaneous coronary intervention; PLEX = plasma exchange; RUE = right upper extremity; SCAI = Society for Cardiovascular Angiography and Interventions; SRA = serotonin release assay; TEG = thromboelastography. ∗Extensive deep vein thrombosis in the right upper extremity including the right internal jugular vein, axillary vein, and brachial vein, in addition to an extensive occlusive thrombus in the right cephalic vein. ˆAcute occlusive thrombus in bilateral peroneal veins, posterior tibial veins, and left gastrocnemius veins. Timeline of the Patient's Clinical Course From Diagnosis of HITT ADAMTS13 = a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; APLS = antiphospholipid syndrome; DES = drug-eluting stent; DVT = deep vein thrombosis; HIPA = heparin-induced platelet activation; HITT = heparin-induced thrombocytopenia with thrombosis; Ig = Immunoglobulin; PCI = percutaneous coronary intervention; PLEX = plasma exchange; RUE = right upper extremity; SCAI = Society for Cardiovascular Angiography and Interventions; SRA = serotonin release assay; TEG = thromboelastography. ∗Extensive deep vein thrombosis in the right upper extremity including the right internal jugular vein, axillary vein, and brachial vein, in addition to an extensive occlusive thrombus in the right cephalic vein. ˆAcute occlusive thrombus in bilateral peroneal veins, posterior tibial veins, and left gastrocnemius veins. History of Presentation A 72-year-old man presented to our facility for exertional chest discomfort and nausea. An initial electrocardiogram obtained in the field showed an inferior ST-segment elevation myocardial infarction (Figure 1). On presentation, urgent coronary angiography was performed, which revealed diffuse mid–right coronary artery (RCA) disease (50%-70% stenosis) with a total mid-to-distal occlusion (Video 1). Two everolimus-eluting stents (SYNERGY, Boston Scientific; 3.5 × 16 mm and 3.0 × 48 mm) were deployed in the mid and distal RCA successfully. The patient was administered a total of 17,000 units of heparin to achieve a therapeutic activated clotting time of 268 seconds. Postprocedure angiography demonstrated slow flow into the distal RCA and posterolateral (PL) branch (TIMI flow grade 1 and 2) with occlusion of the posterior descending artery. Despite the administration of intracoronary nitroglycerin, nicardipine, adenosine, and epinephrine, distal flow did not improve (Video 2). Intravascular ultrasound confirmed optimal stent expansion and apposition; therefore, his findings were attributed to distal microembolization. He was initiated on intravenous tirofiban (0.15 mcg/kg/min) and dual antiplatelet therapy (aspirin [81 mg] and ticagrelor [loading 180 mg and maintenance 90 mg twice daily]) and was admitted to the cardiac telemetry unit for further monitoring.Take-Home Message•Clinicians should consider potential assay interference by ticagrelor when evaluating suspected heparin-induced thrombocytopenia with thrombosis to avoid delayed diagnosis, which could lead to catastrophic outcomes.Figure 1Electrocardiogram on Presentation Showing ST-Segment Elevations in the Inferior Leads Take-Home Message •Clinicians should consider potential assay interference by ticagrelor when evaluating suspected heparin-induced thrombocytopenia with thrombosis to avoid delayed diagnosis, which could lead to catastrophic outcomes. •Clinicians should consider potential assay interference by ticagrelor when evaluating suspected heparin-induced thrombocytopenia with thrombosis to avoid delayed diagnosis, which could lead to catastrophic outcomes. Clinicians should consider potential assay interference by ticagrelor when evaluating suspected heparin-induced thrombocytopenia with thrombosis to avoid delayed diagnosis, which could lead to catastrophic outcomes. Electrocardiogram on Presentation Showing ST-Segment Elevations in the Inferior Leads Sixteen hours after the initial percutaneous coronary intervention, he developed recurrent chest pain with persistent inferior ST-segment elevations and rising lactic acidosis, prompting urgent repeat angiography. Past Medical History The patient had a past medical history of a provoked pulmonary embolism in 2016 in the setting of surgery (for which he received 3 months of anticoagulation, not on anticoagulation on presentation), localized prostate cancer status post-radical prostatectomy in 2020, and hyperlipidemia. Differential Diagnosis The differential diagnosis for acute stent thrombosis included procedure-related mechanical factors (stent underexpansion or malapposition, edge dissection, geographic miss, and residual thrombus burden), inadequate early antithrombotic effect (P2Y12 inhibitor nonresponse or delayed absorption), and underlying hypercoagulable state. Investigations Repeat coronary angiography showed total thrombotic occlusion beginning at the RCA ostium, extending through the previously stented mid and distal segments, with occlusion of the RV marginal branches and posterior descending artery. Extensive thrombus aspiration, angioplasty, and additional stenting (2 everolimus-eluting stents [SYNERGY, Boston Scientific; 5.00 mm x 12 mm and 4.00 mm x 38 mm]) from the ostial to mid RCA restored partial reperfusion (TIMI flow grade 2 to the PL branch and TIMI flow grade 1 to the posterior descending artery) (Video 3). Despite aggressive pharmacologic therapy with tirofiban, systemic heparin, and multiple boluses of intracoronary adenosine and nitroglycerin, sluggish flow persisted (Video 4). Repeat intravascular ultrasound confirmed patent, well-expanded stent segments without malapposition, edge dissection, or another mechanical explanation for acute thrombosis, supporting distal embolization with microvascular obstruction as the most likely proximate mechanism of the persistent slow-flow pattern. The vessel was further treated using a 3 × 150 mm Sterling balloon (Boston Scientific) with prolonged inflation, achieving TIMI flow grade 2 to the PL branch on the final angiographic images (Video 5). However, near the end of the intervention, the patient was hemodynamically unstable, raising the suspicion of cardiogenic shock. Right heart catheterization demonstrated elevated right-sided filling pressures (right atrium: 14 mm Hg; right ventricle: 20/14 mm Hg) and low pulmonary artery oxygen saturation (56%). Pulmonary artery pressures were 20/15 mm Hg (mean: 18 mm Hg) with a pulmonary capillary wedge pressure of 15 mm Hg. Fick cardiac output and cardiac index were reduced at 3.2 L/min and 1.7 L/min/m2, consistent with right ventricular-predominant cardiogenic shock (SCAI Stage D). Blood tests showed lactic acidosis (7.8 mmol/L) and mildly elevated liver transaminase levels, but with preserved renal function. Management The patient was transferred to the cardiac intensive care unit and initiated on inotropic support with epinephrine (5 mcg/min). Two distinct declines in platelet count occurred following heparin exposure: the first 3 days after the index coronary intervention, with spontaneous recovery; the second, progressive and sustained, beginning 6 days after the index procedure. The first occurred 3 days after the index procedure (first heparin exposure); however, the platelet count remained within normal limits and recovered spontaneously. The second, a progressive and sustained decline, began 6 days after the index procedure. Given the clinical suspicion of heparin-induced thrombocytopenia with thrombosis (HITT), heparin was discontinued and replaced with bivalirudin within 48 hours of initial platelet drop (which is approximately 8 days from the first heparin exposure). Hematology was consulted for further evaluation of an underlying hypercoagulable state and alternative causes of thrombocytopenia, including microangiopathic hemolysis, antiphospholipid syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and thrombotic microangiopathy. Comprehensive laboratory evaluation showed mildly reduced ADAMTS13 activity (47%—mild deficiency making thrombotic thrombocytopenic purpura unlikely), attributed to the consumptive and prothrombotic milieu of HITT rather than a primary thrombotic microangiopathy. D-dimer was elevated, consistent with ongoing thrombosis and fibrinolysis. The fibrinogen level was normal, and direct antiglobulin, cold agglutinin, cryoglobulin, β-2 glycoprotein, and anticardiolipin antibody testing produced negative results. The lupus anticoagulant result was indeterminate, consistent with heparin interference. Further testing revealed a strongly positive antiplatelet factor-4/heparin antibody level by enzyme-linked immunosorbent assay, with an optical density of 4.0 (strongly positive), but with a negative serotonin release assay (SRA) result. Despite the negative SRA result, the clinical impression was HITT. Ticagrelor interference with platelet activation was suspected to have produced a false-negative SRA result. After multidisciplinary discussion, ticagrelor was discontinued and replaced with prasugrel (60 mg loading dose followed by 10 mg maintenance dose). Outcome and Follow-Up Despite the transition to bivalirudin, the patient's condition continued to deteriorate, with development of new arterial and multiterritory venous thromboses involving the bilateral upper and lower extremities and acute oliguric renal failure (Figure 2). Intravenous immunoglobulin and plasmapheresis were initiated, given continued thrombotic events. A third SRA test (10 days after switching from ticagrelor to prasugrel) yielded positive results, confirming the suspicion of SRA-negative HITT. Despite appropriate anticoagulation and supportive care in the cardiac intensive care unit, the patient progressed to multiorgan failure and died.Figure 2Acute Limb Ischemia of the Upper and Lower Extremities Acute Limb Ischemia of the Upper and Lower Extremities Discussion/Conclusions HITT is an immune-mediated, prothrombotic reaction caused by IgG antibodies directed against platelet factor 4/heparin complexes, leading to platelet activation, thrombin generation, and thrombosis. Type I HIT is benign, transient thrombocytopenia within the first 2 days of heparin exposure, whereas type II HIT is antibody-mediated and associated with severe, life-threatening thrombocytopenia and thrombosis. Type II HIT presents 5 to 14 days after heparin therapy or within 24 hours of heparin re-exposure in patients with persistent antibodies from exposure within the prior ∼100 days. Risk factors for HITT include the type of heparin exposure, with the highest risk associated with unfractionated heparin, the standard intraprocedural anticoagulant during cardiac catheterization. Diagnosis integrates clinical probability (4T score–Timing of platelet count fall, Thrombosis, oTher causes of thrombocytopenia) and laboratory testing. Our patient's calculated 4T score was 7 (high probability). Immunologic testing (anti-PF4 enzyme-linked immunosorbent assay [ELISA]) revealed strongly positive results, but the SRA, the reference functional assay, produced initial negative results.1 Ticagrelor, a reversible P2Y12 receptor antagonist, is known to inhibit platelet activation through blockade of adenosine diphosphate–dependent signaling, which is essential for the SRA response. Platelet activation by pathogenic HIT antibodies occurs via the FcγRIIA receptor and requires cosignaling through the P2Y12 adenosine diphosphate receptor, which ticagrelor reversibly inhibits.2 This pharmacologic effect can lead to false-negative SRA results despite true antibody-mediated type II HITT. After switching to prasugrel, a repeat SRA yielded positive results, confirming the diagnosis. Similar false-negative cases have been described in the literature, emphasizing that potent P2Y12 inhibitors can suppress functional platelet assays.3,4 In such scenarios, clinicians should rely on clinical judgment, strongly positive anti -PF4/heparin ELISA optical density values (eg, OD >1.5 or >2.0), and, when needed, alternative functional assays such as the PF4 -dependent P-selectin expression assay or other platelet activation assays. When clinical suspicion remains high despite a negative SRA result, clinicians should continue nonheparin anticoagulation, avoid all heparin products, and repeat the SRA or obtain alternative assays while reassessing the 4T score within the full clinical context. Because the SRA is highly sensitive, a negative result should also prompt systematic evaluation of competing explanations, including review of heparin exposure history and concomitant medications that may interfere with functional testing, as highlighted in this case.5 Emerging methods such as serum charcoal filtration to remove ticagrelor before testing may improve diagnostic accuracy.6 In ticagrelor-treated patients with high pretest probability of HITT, a negative SRA should not be reassuring; clinical judgment, ELISA OD magnitude, and assay alternatives should drive management while the assay is repeated after appropriate drug washout or substitution. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.